JP2025060958A5 - - Google Patents
Info
- Publication number
- JP2025060958A5 JP2025060958A5 JP2024232254A JP2024232254A JP2025060958A5 JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5 JP 2024232254 A JP2024232254 A JP 2024232254A JP 2024232254 A JP2024232254 A JP 2024232254A JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- integrin
- rnai agent
- targeting ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| US62/790,372 | 2019-01-09 | ||
| JP2020560257A JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Division JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025060958A JP2025060958A (ja) | 2025-04-10 |
| JP2025060958A5 true JP2025060958A5 (enExample) | 2025-10-08 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210093725A1 (enExample) |
| EP (2) | EP3784269B1 (enExample) |
| JP (2) | JP7704529B2 (enExample) |
| KR (1) | KR102787533B1 (enExample) |
| CN (2) | CN118994152A (enExample) |
| AU (1) | AU2019260738B2 (enExample) |
| BR (1) | BR112020021949A2 (enExample) |
| CA (1) | CA3097656A1 (enExample) |
| DK (1) | DK3784269T3 (enExample) |
| ES (1) | ES2983950T3 (enExample) |
| FI (1) | FI3784269T3 (enExample) |
| HR (1) | HRP20240907T1 (enExample) |
| IL (2) | IL278304B2 (enExample) |
| JO (1) | JOP20200266A1 (enExample) |
| MX (1) | MX2020011290A (enExample) |
| SA (1) | SA520420426B1 (enExample) |
| SG (1) | SG11202009734VA (enExample) |
| SI (1) | SI3784269T1 (enExample) |
| TW (1) | TW202014206A (enExample) |
| WO (1) | WO2019210200A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3120580A1 (en) | 2019-01-09 | 2020-07-16 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| UY39417A (es) * | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
| WO2023283595A2 (en) * | 2021-07-07 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Integrin targeting ligands for ocular delivery of rnai compounds |
| WO2024260259A1 (zh) * | 2023-06-19 | 2024-12-26 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| EA002822B1 (ru) * | 1997-12-17 | 2002-10-31 | Мерк Энд Ко., Инк. | Антагонисты рецептора интегрина |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP3673922A1 (en) * | 2008-03-14 | 2020-07-01 | VisEn Medical, Inc. | Integrin targeting agents and methods of using same |
| ES2605939T3 (es) * | 2012-01-27 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de antagonistas de la integrina para una administración dirigida a células que expresan alfa-V-beta-3 |
| CA2895430C (en) | 2013-01-28 | 2021-11-23 | Janssen Sciences Ireland Uc | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents |
| EP2961843A2 (en) | 2013-02-28 | 2016-01-06 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
| JP6433001B2 (ja) * | 2013-08-07 | 2018-12-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 腫瘍細胞へのＲＮＡｉトリガーのインビボ送達のためのポリ結合体 |
| CN114805342A (zh) * | 2015-02-19 | 2022-07-29 | 赛弗卢尔生命科学公司 | 氟化四氢萘啶基壬酸衍生物及其用途 |
| WO2016172710A2 (en) | 2015-04-24 | 2016-10-27 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| AU2016255494A1 (en) * | 2015-04-30 | 2017-11-02 | Scifluor Life Sciences, Inc. | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
| EA201792103A1 (ru) | 2015-05-29 | 2018-06-29 | Эрроухэд Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии генов hif2альфа |
-
2019
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 US US17/050,042 patent/US20210093725A1/en active Pending
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt unknown
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending